Relmada Therapeutics (RLMD) investor relations material

Investment highlights and pipeline

• NDV-01, a sustained-release Gem/Doce therapy for NMIBC, leads a pipeline of high-value assets with a well-defined regulatory path and strong commercial potential.

• NDV-01 offers improved administration, extended tumor exposure, and physician familiarity compared to conventional therapies.

• Sepranolone, targeting compulsivity disorders, is advancing toward a Phase 2 study in Prader-Willi syndrome.

Market opportunity and disease focus

• NMIBC accounts for 80% of new bladder cancer cases, representing a multi-billion dollar market with high recurrence rates and costly, complex treatment pathways.

• Recurrence rates for high-risk NMIBC are 30–61% within one year, with 50–80% recurrence over five years.

• TURBT procedures are frequent, costly ($7,000–$10,000 each), and carry significant complication rates (>15%).

NDV-01 product profile and advantages

• NDV-01 enables rapid, office-based administration in under 5 minutes, supporting broad adoption in community urology practices.

• Provides sustained intravesical drug release for up to 10 days, enhancing tumor exposure and reducing dosing frequency.

• Biodegradable polymer ensures safe excretion, unlike some competitors requiring device extraction.